SMALL-BATCH cGMP. BIG CLINICAL POSSIBILITIES.
From promising science to your first patient. Bench To Batch brings agile, phase-appropriate manufacturing and regulatory expertise together—built for early-stage biotech.
YOUR SCIENCE. YOUR STAGE. YOUR PATHWAY.
Not every program needs a commercial-scale solution. Find the right starting point for yours.
An informed starting point—not a substitute for a program-specific CMC assessment.
YOUR PHASE-APPROPRIATE OVERVIEW
Process development & regulatory planning
Assess expression, purification, potency and single-use process compatibility. Evaluate 50–200 l as a planning range, subject to yield, dose and process fit.
Avoid scaling too early
Locking in commercial-scale capacity before clinical demand is defined.
A BRIDGE. NOT A BOTTLENECK.
Keep early development agile. Build the bridge to commercial scale when the science is ready.
BUILD THE FOUNDATION
Process development, characterization and a regulatory strategy grounded in your science.
REACH YOUR FIRST PATIENT
Right-sized clinical manufacturing with quality controls and CMC execution moving together.
TRANSFER WHEN YOU’RE READY
A documented process and knowledge package for a de-risked commercial technology transfer.
Traditional mega-CDMO
Commercial-first infrastructure
Bench To Batch bridge
Phase-appropriate execution
Batch: Right-sized clinical manufacturing with quality controls and CMC execution moving together.
*Illustrative comparison based on planning assumptions, not a promised schedule. Facility availability, modality, process readiness, testing and regulatory feedback determine actual timelines.
ONE PLATFORM. TWO CONNECTED DISCIPLINES.
As a division of Innovative Regulatory Science Group, Bench To Batch connects your manufacturing pathway with your regulatory strategy. Process, quality and CMC documentation move in the same direction—from day one.
KNOWLEDGE THAT MOVES YOU FORWARD
Practical perspectives at the intersection of manufacturing and regulatory science.
YOUR NEXT MILESTONE STARTS HERE.
Manufacturing and regulatory strategy. One connected conversation.